Braster S.A. Stock

BRA

PLBRSTR00014

Biotechnology & Medical Research

Delayed Warsaw S.E. 20:55:52 27/11/2025 +04			5-day change	1st Jan Change
0.5800 ^PLN	-.--%		-.--%	-

29/05/24	Braster S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/11/23	Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Braster SA w restrukturyzacji, formerly Braster SA, is a Poland-based company principally engaged in the bio diagnostics and testing. The Company provides research and development on breast cancer. It applies liquid crystals and liquid crystal emulsion formula that is used to produce liquid crystal matrix based on LCD technology, continuous film CLCF (Continuous Liquid Crystal Film) in the diagnosis of breast cancer. Its main product is Braster Tester, which is a device that uses thermographic liquid crystal matrices for diagnosing breast cancer; the device is made up of three film matrices covered with a liquid crystal mixture that allows thermal imaging. The Company cooperates with the Jagiellonian University, with the participation of the clinical trial conducted by Thermacrac, among others.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	17.04M 4.33M 3.87M 3.58M 3.24M 6.07M 412M 6.17M 43.08M 215M 16.24M 15.9M 682M	P/E 2022	-5.18x	P/E 2023	-3.55x
Enterprise Value	28.34M 7.2M 6.44M 5.95M 5.39M 10.09M 685M 10.26M 71.66M 358M 27.01M 26.44M 1.13B	EV / Sales 2022	15.4x	EV / Sales 2023	88.9x
Free-Float	80.79%	Yield 2022 *	-	Yield 2023	-

29/05/24	Braster S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/11/23	Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
04/10/23	Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
25/05/23	Braster S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
03/05/23	Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
03/05/23	Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
21/11/22	Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
27/09/22	Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
25/05/22	Braster S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
03/05/22	Braster S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
30/11/21	Braster S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
01/10/21	Braster S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	CI
23/09/21	An unknown buyer acquired 21.38% stake in Braster S.A. from Carom Sp. z o.o.	CI

5 years	0.53		1.52
10 years	0.19		23.4

Director	Title	Age	Since
Katarzyna Kilijanczyk BRD	Director/Board Member	-	-
Elzbieta Kozik BRD	Director/Board Member	-	-
Zygfryd Kosidowski BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRASTER S.A.	-.--%	-.--%	-	-	4.61M
WUXI APPTEC CO., LTD.	+0.88%	+1.18%	+40.64%	+74.91%	64.69B
ARGENX SE	-0.26%	+7.23%	+11.14%	+74.78%	54.78B
LONZA GROUP AG	+0.47%	+5.10%	+8.22%	+101.52%	53.49B
IQVIA HOLDINGS INC.	-2.06%	+2.51%	+24.07%	+50.98%	45.98B
BEONE MEDICINES AG	-1.79%	+0.49%	+19.32%	+122.77%	42.94B
REVOLUTION MEDICINES, INC.	-1.65%	+3.34%	+237.56%	+819.04%	40.08B
CELLTRION, INC.	-2.26%	-2.06%	+15.38%	+45.14%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	+0.22%	-4.77%	+26.59%	+0.55%	23.97B
GENMAB A/S	+12.10%	+18.47%	+55.14%	+45.58%	23.67B
Average	+0.56%	+2.00%	+48.67%	+148.36%	38.31B
Weighted average by Cap.	+0.12%	+2.59%	+45.92%	+149.88%

Braster S.A. Stock

Stocks

BRA

PLBRSTR00014

Biotechnology & Medical Research

Valuation: Braster S.A.

Chart: Braster S.A.

Latest news: Braster S.A.

Price Extremes

Managers and Directors: Braster S.A.

Bio Diagnostics & Testing

Financials

Company Profile

	2022	2023
Net sales	2.24M 569K 509K 471K 426K 797K 54.12M 811K 5.66M 28.31M 2.13M 2.09M 89.62M	319K 81.01K 72.44K 67.02K 60.68K 114K 7.71M 115K 806K 4.03M 304K 298K 12.76M
Net income	-3.87M -983K -879K -813K -737K -1.38M -93.55M -1.4M -9.79M -48.93M -3.69M -3.61M -155M	-4.75M -1.21M -1.08M -997K -903K -1.69M -115M -1.72M -12M -60M -4.53M -4.43M -190M
Net Debt	12.42M 3.15M 2.82M 2.61M 2.36M 4.42M 300M 4.49M 31.39M 157M 11.83M 11.58M 497M	11.3M 2.87M 2.57M 2.37M 2.15M 4.02M 273M 4.09M 28.57M 143M 10.77M 10.54M 452M